{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:03:56Z","timestamp":1760645036306},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.nucmedbio.2004.12.006","type":"journal-article","created":{"date-parts":[[2005,4,8]],"date-time":"2005-04-08T13:19:02Z","timestamp":1112966342000},"page":"293-299","source":"Crossref","is-referenced-by-count":4,"title":["In vivo evaluation of [123I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies"],"prefix":"10.1016","volume":"32","author":[{"given":"Ludovicus","family":"Staelens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Oltenfreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Blanckaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Kersemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Vandenbulcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Van De Wiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Slegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2004.12.006_bib1","series-title":"Essential psychopharmacology","author":"Stahl","year":"2000"},{"issue":"4238","key":"10.1016\/j.nucmedbio.2004.12.006_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor-binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"issue":"4194","key":"10.1016\/j.nucmedbio.2004.12.006_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic-drugs \u2014 direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0014-2999(98)00312-4","article-title":"Dopamine D2 and D4 ligands: relation to antipsychotic action","volume":"351","author":"Wilson","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib6","first-page":"94","article-title":"PET examination of central D2 receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs","volume":"10","author":"Farde","year":"1993","journal-title":"Psychopharmacol. Ser."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib8","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/0014-2999(95)00677-D","article-title":"Schizophrenia-elevation of dopamine D-4-like sites, using [H-3] nemonapride and [I-125]epidepride","volume":"286","author":"Seeman","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/365441a0","article-title":"Dopamine receptors elevated in schizophrenia","volume":"365","author":"Seeman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib10","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1046\/j.1471-4159.1994.63041576.x","article-title":"Are striatal dopamine D-4 receptors increased in schizophrenia","volume":"63","author":"Reynolds","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib11","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1016\/0014-2999(95)00408-D","article-title":"Absence of detectable striatal dopamine D-4 receptors in drug-treated schizophrenia","volume":"281","author":"Reynolds","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","article-title":"Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors","volume":"3","author":"Seeman","year":"1998","journal-title":"Mol. Psychiatry"},{"issue":"17","key":"10.1016\/j.nucmedbio.2004.12.006_bib13","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1021\/jm970170v","article-title":"Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D-4 receptor antagonists as potential antipsychotic agents","volume":"40","author":"Unangst","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0969-8051(02)00293-7","article-title":"Synthesis and evaluation of 3-(4-chlorobenzyl)-8-[C-11]methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one: a PET tracer for imaging sigma(1) receptors","volume":"29","author":"Zhang","year":"2002","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"10.1016\/j.nucmedbio.2004.12.006_bib15","first-page":"1020","article-title":"Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1","volume":"282","author":"Primus","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.nucmedbio.2004.12.006_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02988264","article-title":"Age-related changes of the binding of [3H]SA4503 to sigma1 receptors in the rat brain","volume":"17","author":"Ishiwata","year":"2003","journal-title":"Ann. Nucl. Med."},{"issue":"1","key":"10.1016\/j.nucmedbio.2004.12.006_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(00)00348-4","article-title":"Binding properties of [3H]MS-377, a novel sigma receptor ligand, to rat brain membranes","volume":"400","author":"Karasawa","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nucmedbio.2004.12.006_bib18","doi-asserted-by":"crossref","unstructured":"Staelens L, Oltenfreiter R, Cornelissen B, Blanckaert P, De Vos F, Deforce D, et al. Synthesis of [123I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one, a potential dopamine D4 ligand for SPECT studies. Journal of Labelled Compounds Radiopharmaceuticals [in press].","DOI":"10.1002\/jlcr.902"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805104001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805104001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T08:34:53Z","timestamp":1549787693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805104001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0969805104001866"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2004.12.006","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}